Jacobs Levy Equity Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $6.79M | Sell |
54,000
-34,915
| -39% | -$4.39M | 0.03% | 373 |
|
|
2025
Q1 | $9.83M | Buy |
88,915
+21,726
| +32% | +$2.4M | 0.04% | 340 |
|
|
2024
Q4 | $9.17M | Sell |
67,189
-456,979
| -87% | -$62.4M | 0.03% | 320 |
|
|
2024
Q3 | $60.4M | Sell |
524,168
-196,919
| -27% | -$22.7M | 0.23% | 106 |
|
|
2024
Q2 | $99.3M | Buy |
721,087
+8,289
| +1% | +$1.14M | 0.41% | 58 |
|
|
2024
Q1 | $98.3M | Sell |
712,798
-40,067
| -5% | -$5.53M | 0.44% | 53 |
|
|
2023
Q4 | $99.2M | Buy |
752,865
+60,491
| +9% | +$7.97M | 0.5% | 46 |
|
|
2023
Q3 | $77.9M | Buy |
692,374
+256,920
| +59% | +$28.9M | 0.46% | 54 |
|
|
2023
Q2 | $41.1M | Buy |
435,454
+4,118
| +1% | +$388K | 0.24% | 108 |
|
|
2023
Q1 | $43.7M | Buy |
431,336
+367,229
| +573% | +$37.2M | 0.27% | 94 |
|
|
2022
Q4 | $7.66M | Buy |
64,107
+50,540
| +373% | +$6.04M | 0.05% | 320 |
|
|
2022
Q3 | $1.44M | Buy |
+13,567
| New | +$1.44M | 0.01% | 629 |
|
|
2021
Q1 | – | Sell |
-6,308
| Closed | -$605K | – | 1086 |
|
|
2020
Q4 | $605K | Sell |
6,308
-25,173
| -80% | -$2.41M | 0.01% | 823 |
|
|
2020
Q3 | $3.03M | Buy |
31,481
+3,947
| +14% | +$380K | 0.03% | 441 |
|
|
2020
Q2 | $3.36M | Sell |
27,534
-122,910
| -82% | -$15M | 0.04% | 426 |
|
|
2020
Q1 | $13M | Sell |
150,444
-11,388
| -7% | -$986K | 0.17% | 148 |
|
|
2019
Q4 | $17.4M | Buy |
161,832
+47,903
| +42% | +$5.15M | 0.17% | 148 |
|
|
2019
Q3 | $10.3M | Sell |
113,929
-20,450
| -15% | -$1.84M | 0.13% | 206 |
|
|
2019
Q2 | $11.3M | Buy |
134,379
+50,210
| +60% | +$4.24M | 0.16% | 172 |
|
|
2019
Q1 | $7.42M | Buy |
+84,169
| New | +$7.42M | 0.11% | 258 |
|